Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Venus Remedies secures marketing authorization in Philippines
For people with relapsed or refractory diffuse large B-cell lymphoma
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Subscribe To Our Newsletter & Stay Updated
